Ascletis Pharma, Inc. ( (HK:1672) ) has issued an announcement.
Ascletis Pharma Inc. announced positive results from its U.S. Phase Ia study of the ASC30 oral tablet, a small molecule GLP-1R agonist intended for obesity treatment. The study showed that ASC30 has promising pharmacokinetic properties, including a long half-life and dose-proportionality, suggesting potential for once-daily dosing without food restrictions. The tablet was generally safe and well-tolerated, with only mild to moderate gastrointestinal adverse events reported, supporting its potential as a best-in-class treatment option. The company’s progress in developing ASC30 could enhance its positioning in the obesity treatment market.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biotechnology company based in the Cayman Islands, focusing on the development of innovative drugs, particularly in the field of small molecule oral GLP-1R agonists for treating conditions such as obesity.
YTD Price Performance: 32.89%
Average Trading Volume: 2,647,146
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$4.03B
See more insights into 1672 stock on TipRanks’ Stock Analysis page.